Reunion Neuroscience’s single-dose RE104 met the primary endpoint in the Phase 2 RECONNECT study for postpartum depression (PPD), delivering a 23.0-point reduction from baseline in MADRS at Day 7 with the 30 mg dose versus an active low-dose control (p=0.0094). Clinically meaningful improvements were observed as early as Day 1 and maintained through Day 28, with favorable signals across response and remission on MADRS and additional measures of anxiety, global improvement, and maternal function.
The company has completed an End of Phase 2 meeting and reports FDA alignment on a registrational path that could be satisfied with one successful Phase 3 trial, planned to start in 2026. RECONNECT randomized 84 adult female patients with moderate-to-severe PPD (HAMD-17 ≥24) to a single subcutaneous 30 mg dose or a subperceptual 1.5 mg dose to maintain blinding. Baseline disease severity was comparable between arms (mean MADRS ~33), though more patients in the 30 mg arm were on concurrent SSRI and/or therapy at baseline, an imbalance that will need prospectively managed stratification in Phase 3. Safety and tolerability were assessed but detailed AE rates were not disclosed in the announcement.
Strategically, this program positions a psychedelic-inspired, short-acting intervention against a PPD landscape defined by GABAergic neurosteroids and conventional SSRIs. The bet is that a rapid, durable effect from a single visit can meet clinical urgency in PPD while avoiding the operational drag of multi-week dosing or prolonged psychoactive sessions typical of other serotonergic agents. A shorter in-session duration, subcutaneous administration, and the absence of an infusion requirement create a pragmatic counterpoint to hospital-based IV brexanolone and could sidestep some adherence and access frictions inherent to two-week oral regimens.
For sites, a condensed, outpatient-compatible protocol may translate into fewer bed-hours and staffing blocks compared with infusion therapies or full-day psychedelic sessions, potentially expanding the pool of community sites able to participate. That matters in PPD, where childcare, transportation, and lactation considerations constrain visit feasibility. At the same time, psychedelic trials bring their own operational demands: standardized psychological support, trained facilitators, robust blinding strategies, and careful management of set and setting. The use of an active low-dose control in Phase 2 speaks to blinding concerns; Phase 3 will need to balance assay sensitivity with regulatory expectations for control selection and interpretability.
Regulators are likely to focus on consistency of effect across postpartum time windows, maternal-infant safety, suicidality monitoring, and drug exposure during breastfeeding. Payers will look beyond symptom scores to functional recovery, including maternal role performance and anxiety relief, and will compare durability beyond 28 days against approved options. The noted baseline imbalance in concomitant treatments underscores the importance of stratification, predefined sensitivity analyses, and transparent handling of background therapy to secure clean efficacy attribution.
Next, watch for Phase 3 design specifics: control arm choice (placebo, subperceptual active, or active comparator), stratification by baseline therapy and postpartum timing, integration of functional endpoints such as BIMF, and plans for lactation pharmacokinetics. Clarity on adverse event profiles, session duration, and the extent of required psychological support will shape site readiness and potential REMS considerations. If the single pivotal trial proceeds, DEA scheduling and therapy-delivery infrastructure could become gating factors for commercialization. The pivotal question is whether RE104 can reproduce rapid, durable benefit with operational simplicity at scale—enough to compete in a category where speed of onset, logistics, and maternal function now carry as much weight as symptom reduction.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
